The bivalent Norovirus GII.4 oral tablet vaccine developed by Vaxart is moving forward–the initiation of a Phase 1b clinical trial. “The initiation of the bivalent norovirus vaccine Phase 1b trial...

Vaxart, Inc., a privately-held, clinical stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, announced today that its H1 influenza oral tablet...